174 related articles for article (PubMed ID: 38596654)
21. Pathophysiologically based drug treatment of sickle cell disease.
Steinberg MH
Trends Pharmacol Sci; 2006 Apr; 27(4):204-10. PubMed ID: 16530854
[TBL] [Abstract][Full Text] [Related]
22. Potential role of LSD1 inhibitors in the treatment of sickle cell disease: a review of preclinical animal model data.
Rivers A; Jagadeeswaran R; Lavelle D
Am J Physiol Regul Integr Comp Physiol; 2018 Oct; 315(4):R840-R847. PubMed ID: 30067082
[TBL] [Abstract][Full Text] [Related]
23. Reticulocyte mitochondrial retention increases reactive oxygen species and oxygen consumption in mouse models of sickle cell disease and phlebotomy-induced anemia.
Gallivan A; Alejandro M; Kanu A; Zekaryas N; Horneman H; Hong LK; Vinchinsky E; Lavelle D; Diamond AM; Molokie RE; Ramasamy J; Rivers A
Exp Hematol; 2023 Jun; 122():55-62. PubMed ID: 36934777
[TBL] [Abstract][Full Text] [Related]
24. Nitric oxide reduces sickle hemoglobin polymerization: potential role of nitric oxide-induced charge alteration in depolymerization.
Ikuta T; Thatte HS; Tang JX; Mukerji I; Knee K; Bridges KR; Wang S; Montero-Huerta P; Joshi RM; Head CA
Arch Biochem Biophys; 2011 Jun; 510(1):53-61. PubMed ID: 21457702
[TBL] [Abstract][Full Text] [Related]
25. Etavopivat, a Pyruvate Kinase Activator in Red Blood Cells, for the Treatment of Sickle Cell Disease.
Schroeder P; Fulzele K; Forsyth S; Ribadeneira MD; Guichard S; Wilker E; Marshall CG; Drake A; Fessler R; Konstantinidis DG; Seu KG; Kalfa TA
J Pharmacol Exp Ther; 2022 Mar; 380(3):210-219. PubMed ID: 35031585
[TBL] [Abstract][Full Text] [Related]
26. Sickle cell biomechanics.
Barabino GA; Platt MO; Kaul DK
Annu Rev Biomed Eng; 2010 Aug; 12():345-67. PubMed ID: 20455701
[TBL] [Abstract][Full Text] [Related]
27. Inhibition of Band 3 tyrosine phosphorylation: a new mechanism for treatment of sickle cell disease.
Noomuna P; Risinger M; Zhou S; Seu K; Man Y; An R; Sheik DA; Wan J; Little JA; Gurkan UA; Turrini FM; Kalfa T; Low PS
Br J Haematol; 2020 Aug; 190(4):599-609. PubMed ID: 32346864
[TBL] [Abstract][Full Text] [Related]
28. Established and experimental treatments for sickle cell disease.
De Franceschi L; Corrocher R
Haematologica; 2004 Mar; 89(3):348-56. PubMed ID: 15020275
[TBL] [Abstract][Full Text] [Related]
29. Heterogeneous red blood cell adhesion and deformability in sickle cell disease.
Alapan Y; Little JA; Gurkan UA
Sci Rep; 2014 Nov; 4():7173. PubMed ID: 25417696
[TBL] [Abstract][Full Text] [Related]
30. Potential of isoquercitrin as antisickling agent: a multi-spectroscopic, thermophoresis and molecular modeling approach.
Syed MM; Doshi PJ; Dhavale DD; Doshi JB; Kate SL; Kulkarni G; Sharma N; Uppuladinne M; Sonavane U; Joshi R; Kulkarni MV
J Biomol Struct Dyn; 2020 Jun; 38(9):2717-2736. PubMed ID: 31315526
[TBL] [Abstract][Full Text] [Related]
31. Pathophisiology of sickle cell disease and new drugs for the treatment.
De Franceschi L
Mediterr J Hematol Infect Dis; 2009 Dec; 1(1):e2009024. PubMed ID: 21415994
[TBL] [Abstract][Full Text] [Related]
32. Variation in fetal hemoglobin parameters and predicted hemoglobin S polymerization in sickle cell children in the first two years of life: Parisian Prospective Study on Sickle Cell Disease.
Maier-Redelsperger M; Noguchi CT; de Montalembert M; Rodgers GP; Schechter AN; Gourbil A; Blanchard D; Jais JP; Ducrocq R; Peltier JY
Blood; 1994 Nov; 84(9):3182-8. PubMed ID: 7524767
[TBL] [Abstract][Full Text] [Related]
33. Electrical Impedance Characterization of Erythrocyte Response to Cyclic Hypoxia in Sickle Cell Disease.
Liu J; Qiang Y; Alvarez O; Du E
ACS Sens; 2019 Jul; 4(7):1783-1790. PubMed ID: 31083931
[TBL] [Abstract][Full Text] [Related]
34. Microfluidic assessment of red blood cell mediated microvascular occlusion.
Man Y; Kucukal E; An R; Watson QD; Bosch J; Zimmerman PA; Little JA; Gurkan UA
Lab Chip; 2020 Jun; 20(12):2086-2099. PubMed ID: 32427268
[TBL] [Abstract][Full Text] [Related]
35. Ektacytometric measurement of sickle cell deformability as a continuous function of oxygen tension.
Sorette MP; Lavenant MG; Clark MR
Blood; 1987 Jan; 69(1):316-23. PubMed ID: 3790727
[TBL] [Abstract][Full Text] [Related]
36. Sickling of nucleated erythroid precursors from patients with sickle cell anemia.
Hasegawa S; Rodgers GP; Dwyer N; Noguchi CT; Blanchette-Mackie EJ; Uyesaka N; Schechter AN; Fibach E
Exp Hematol; 1998 Apr; 26(4):314-9. PubMed ID: 9546314
[TBL] [Abstract][Full Text] [Related]
37. Effects of nitric oxide and its congeners on sickle red blood cell deformability.
Belanger AM; Keggi C; Kanias T; Gladwin MT; Kim-Shapiro DB
Transfusion; 2015 Oct; 55(10):2464-72. PubMed ID: 25912054
[TBL] [Abstract][Full Text] [Related]
38. βT87Q-Globin Gene Therapy Reduces Sickle Hemoglobin Production, Allowing for
Demirci S; Gudmundsdottir B; Li Q; Haro-Mora JJ; Nassehi T; Drysdale C; Yapundich M; Gamer J; Seifuddin F; Tisdale JF; Uchida N
Mol Ther Methods Clin Dev; 2020 Jun; 17():912-921. PubMed ID: 32405513
[TBL] [Abstract][Full Text] [Related]
39. Design, Synthesis, and Evaluation of Allosteric Effectors for Hemoglobin.
Enakaya NA; Jefferson A; Chew-Martinez D; Matthews JS
Acc Chem Res; 2023 Jun; 56(11):1279-1286. PubMed ID: 36946781
[TBL] [Abstract][Full Text] [Related]
40. Static and dynamic rigidities of normal and sickle erythrocytes. Major influence of cell hemoglobin concentration.
Evans E; Mohandas N; Leung A
J Clin Invest; 1984 Feb; 73(2):477-88. PubMed ID: 6699172
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
